within Pharmacolibrary.Drugs.ATC.N;

model N03AX03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 0.0013333333333333333,
    adminDuration  = 600,
    adminMass      = 0.2,
    adminCount     = 1,
    Vd             = 0.0005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0033333333333333335,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Sultiame is a carbonic anhydrase inhibitor used as an anticonvulsant, primarily for the treatment of epilepsy, particularly in children with benign childhood epilepsy with centrotemporal spikes (BECTS). It is not approved in all countries and its use is mainly in Europe and Australia.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are estimated for adults based on sparse data and secondary literature sources as primary literature with detailed compartmental PK modeling is lacking.</p><h4>References</h4><ol><li>Philip N Patsalos, Edgar P Spencer, Dave J Berry,Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update.,Therapeutic drug monitoring,2018<a href='https://pubmed.ncbi.nlm.nih.gov/29957667/'>https://pubmed.ncbi.nlm.nih.gov/29957667/</a></li><li>Kim Dao, Paul Thoueille, Laurent A Decosterd, Thomas Mercier, Monia Guidi, Carine Bardinet, Sébastien Lebon, Eva Choong, Arnaud Castang, Catherine Guittet, Luc-André Granier, Thierry Buclin,Sultiame pharmacokinetic profile in plasma and erythrocytes after single oral doses: A pilot study in healthy volunteers.,Pharmacology research & perspectives,2020<a href='https://pubmed.ncbi.nlm.nih.gov/31990440/'>https://pubmed.ncbi.nlm.nih.gov/31990440/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N03AX03;
